AbCellera (ABCL) Is Up 24.5% After Strong Q2 Revenue Beat and Advancing Clinical Pipeline [Yahoo! Finance]
AbCellera Biologics Inc. - Common Shares (ABCL)
Company Research
Source: Yahoo! Finance
significant milestone payment from a Trianni license, alongside the initiation of a Phase 1 trial for its investigational antibody therapy ABCL575 and appointment of a new Chief Medical Officer. These developments have drawn increased attention to AbCellera's growing clinical pipeline and its progress transitioning from a platform company to a clinical-stage biotech innovator. We'll examine how AbCellera's better-than-expected quarterly revenue figures may affect the company's investment narrative and future outlook. Uncover the next big thing with financially sound penny stocks that balance risk and reward AbCellera Biologics Investment Narrative Recap Owning AbCellera Biologics stock means believing the company can successfully transition from a drug discovery platform to a clinical-stage biotech by advancing its internal antibody pipeline, all while addressing high research spending and translating strong clinical promise into actual marketable therapies. The recent Q2 20
Show less
Read more
Impact Snapshot
Event Time:
ABCL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABCL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABCL alerts
High impacting AbCellera Biologics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ABCL
News
- AbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss [Yahoo! Finance]Yahoo! Finance
- Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? [Yahoo! Finance]Yahoo! Finance
- The Best Canadian Stock You've Never Heard of [Yahoo! Finance Canada]Yahoo! Finance Canada
- AbCellera Appoints Dr. Stephen Quake to its Board of DirectorsBusiness Wire
ABCL
Earnings
- 11/6/25 - Miss
ABCL
Sec Filings
- 11/28/25 - Form 8-K
- 11/26/25 - Form 4
- 11/12/25 - Form 8-K
- ABCL's page on the SEC website